10 Facts About Parke-Davis

In 1970 Parke-Davis was acquired by Warner-Lambert, which in turn was acquired by Pfizer in 2000.

Parke-Davis produced an herbal laxative drug Cascara found from Native Americans in the Pacific Northwest.

The Parke-Davis Research Laboratory is a National Historic Landmark; the surrounding Parke-Davis and Company Pharmaceutical Company Plant is on the National Register of Historic Places.

Parke-Davis commissioned Detroit illustrator Robert Thom to produce 40 illustrations for the series, “A History of Pharmacy in Pictures.

In 2004, Pfizer "admitted that Parke-Davis aggressively marketed Neurontin by illicit means for unrelated conditions including bipolar disorder, pain, migraine headaches, and drug and alcohol withdrawal", and consented to $430 million in penalties although it claimed the violations originated in 1996, well before Pfizer's acquisition of Warner-Lambert.

Related searches

One of Parke-Davis' early products was an amylase isolated from Aspergillus oryzae by Dr Jokichi Takamine.

Also, Parke-Davis distributed Coley's toxins, the first cancer vaccine, which was developed by William Coley to treat osteosarcoma.

Parke-Davis marketed the first widely available epilepsy treatment, Dilantin, which was approved in 1939, although it discovered neither the compound nor the application on its own.

Parke-Davis developed the first bacterial vaccine, and the company was thus known as a pioneer in the field of vaccinology.

Parke-Davis produced the broad-spectrum antibiotic chloramphenicol, which was a blockbuster product before the discovery of its association with aplastic anemia.